Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Oct 2, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment for people with type 1 diabetes who have kidney problems, known as diabetic nephropathy. The researchers want to see if combining two medications, sotagliflozin and ambrisentan, can help protect the kidneys better than when using either medication alone. This study is still in the planning stages and hasn’t started recruiting participants yet.

To participate, individuals must be between 18 and 64 years old, have been diagnosed with type 1 diabetes for at least six months, and have specific kidney health measurements. Participants should also have a good understanding of their diabetes management and be able to monitor their blood sugar at home. Throughout the study, participants will receive regular check-ups and assessments to ensure their safety and to monitor the effectiveness of the treatment. If you or someone you know is interested, please keep in mind the eligibility criteria and that the trial is currently not recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing and able to sign informed consent
• • Male or female individuals diagnosed with type 1 diabetes at least 6 months prior to informed consent
• • WOCBP must have a negative pregnancy test at screening and must not be lactating.
• • Male individuals must use highly effective method of contraception for the duration of the study (from the time they sign consent) and for 4 weeks after the last dose of study medication, or be able to provide proof of vasectomy.
• • Female individuals must use highly effective method of contraception for the duration of the study (from the time they sign consent) and for 4 weeks after the last dose of study medication, provide proof of hysterectomy or sterilization, or be deemed menopausal based on a FSH-test.
• • Age ≥18 and \<65years, at the time of signing consent.
• • Body Mass Index ≥ 21 kg/m2
• • Urinary albumin:creatinine ratio ≥ 50 mg/g and \<3000 mg/g
• • eGFR \> 30 and \<90 ml/min/1.73m2
• • Stable RAAS inhibition medication for at least 4 weeks prior to screening
• • HbA1c between 6.5 and 10.5%
• * Based on the Investigator's judgment participant must have a good understanding of his/her disease and how to manage it, and be willing and capable of performing the following study assessments (assessed before randomization):
• • patient-led management and adjustment of insulin therapy
• • reliable approach to insulin dose adjustment for meals, such as carbohydrate counting
• • reliable and regular home-based blood glucose monitoring
• • established "sick day" management regimen
• Exclusion Criteria:
• • Diagnosis of type 2 diabetes
• • Treatment with an antihyperglycaemic agent (e.g., metformin, alpha-glucosidase inhibitors, pramlintide, glucagon-like peptide receptor agonist, etc.) within 3 months
• • Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that required hospitalisation or hypoglycaemia-related treatment by an emergency physician or paramedic within 3 months
• • Hypoglycaemia unawareness based on Investigator judgement or frequent episodes of unexplained hypoglycaemia (2 or more unexplained episodes within 3 months)
• • Occurrence of diabetic ketoacidosis within 6 months prior to study enrolment
• • Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or transient ischemic attack within 6 months
• • Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g., immunocompromised patients, patients who might be at higher risk of developing urinary, genital or mycotic infections, patients with chronic viral infections, etc.)
• • Treatment with an SGLT2i within 30 days of Visit 1
• • Diagnosis of severe edema (per investigator judgment) or heart failure (NYHC stage III or IV)